Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis
暂无分享,去创建一个
M. Honda | S. Kaneko | Y. Nakanuma | H. Misu | T. Takamura | Y. Zen | E. Mizukoshi | K. Arai | T. Yamashita | Kazutoshi Yamada | S. Kitamura | H. Sunagozaka | Y. Takeshita
[1] R. Matsumori,et al. Elovl6 promotes nonalcoholic steatohepatitis , 2012, Hepatology.
[2] Xiuying Zhang,et al. Liver fatty acid composition in mice with or without nonalcoholic fatty liver disease , 2011, Lipids in Health and Disease.
[3] A. Feldstein,et al. Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo‐controlled trial , 2011, Hepatology.
[4] V. Ratziu,et al. An overview of nonalcoholic steatohepatitis: past, present and future directions. , 2010, Journal of gastrointestinal and liver diseases : JGLD.
[5] B. Neuschwander‐Tetri,et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.
[6] S. Klein,et al. Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications , 2010, Hepatology.
[7] Hirokazu Takahashi,et al. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. , 2009, Journal of hepatology.
[8] A. Feldstein,et al. Hepatic Lipid Partitioning and Liver Damage in Nonalcoholic Fatty Liver Disease , 2009, Journal of Biological Chemistry.
[9] M. Miyazaki,et al. Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. , 2007, Cell metabolism.
[10] Hitoshi Shimano,et al. Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance , 2007, Nature Medicine.
[11] Michelle M Wiest,et al. A lipidomic analysis of nonalcoholic fatty liver disease , 2007, Hepatology.
[12] M. Honda,et al. Different signaling pathways in the livers of patients with chronic hepatitis B or chronic hepatitis C , 2006, Hepatology.
[13] K. Flegal,et al. Prevalence of overweight and obesity in the United States, 1999-2004. , 2006, JAMA.
[14] M. Pagliassotti,et al. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. , 2006, Endocrinology.
[15] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[16] J. Jessurun,et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.
[17] A. Diehl,et al. Cytokines and the pathogenesis of non-alcoholic steatohepatitis , 2005, Gut.
[18] J. Horton,et al. Molecular mediators of hepatic steatosis and liver injury. , 2004, The Journal of clinical investigation.
[19] Robert V Farese,et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[20] R. Karim,et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome , 2002, Hepatology.
[21] J. Clore,et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.
[22] K. Batts,et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.
[23] I. Shimomura,et al. Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[24] Z. Younossi,et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.
[25] R. DeFronzo,et al. Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.
[26] Shohei Matsuzaki,et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background , 2003, Journal of Gastroenterology.